Cite
HARVARD Citation
Dubsky, P. et al. (2020). The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial. European journal of cancer. pp. 99-106. [Online].